Vynca Revenue and Competitors
Estimated Revenue & Valuation
- Vynca's estimated annual revenue is currently $11.3M per year.
- Vynca's estimated revenue per employee is $145,000
Employee Data
- Vynca has 78 Employees.
- Vynca grew their employee count by -15% last year.
Vynca's People
| Name | Title | Email/Phone |
|---|
Vynca Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.7M | 32 | 10% | N/A | N/A |
#2 | $43.7M | 274 | 1% | N/A | N/A |
#3 | $17.1M | 118 | 22% | N/A | N/A |
#4 | $1460M | 8706 | 7% | $1.1B | N/A |
#5 | $322.4M | 1588 | 20% | N/A | N/A |
#6 | $201.8M | 994 | -5% | N/A | N/A |
#7 | $235.1M | 1134 | -33% | $101.6M | N/A |
#8 | $581.3M | 2843 | 9% | $253.1M | N/A |
#9 | $604.5M | 2978 | -16% | N/A | N/A |
#10 | $833.5M | 4106 | 52% | N/A | N/A |
What Is Vynca?
Vynca addresses critical unmet needs in end-of-life care with comprehensive advance care planning technology solutions that enable healthcare organizations to deliver high-quality treatment consistent with individuals' preferences. The company has digitized a previously paper-based process to help patients, families and providers have meaningful conversations about future care preferences, create accurate documentation and provide real-time access to this critical information throughout the care continuum. With a zero percent error rate, Vynca ensures personalized end-of-life care is available for every individual, every time – reducing medical errors, adverse efforts and unwanted healthcare utilization, while improving patient, caregiver and clinician experience.
keywords:N/AN/A
Total Funding
78
Number of Employees
$11.3M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.3M | 78 | 32% | N/A |
#2 | $11.3M | 78 | -5% | $23M |
#3 | $11.3M | 78 | 0% | N/A |
#4 | $23.4M | 78 | -16% | N/A |
#5 | $12.2M | 79 | 32% | N/A |
